noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Office of the Colorado Attorney[...]

Attorney General Phil Weiser: Commuting Tina Peters' prison sentence[...]
Ducommun Incorporated

Statement of Changes in Beneficial Ownership (Form 4)
City of Hope

City of Hope Cancer Center Chicago Appoints Dr. Monica Malec as Chief[...]

Healthcare

Indivior Pharmaceuticals Inc.

05/15/2026 | Press release | Distributed by Public on 05/15/2026 14:03

Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) Effective June 1, 2026, Indivior Pharmaceuticals, Inc. (the "Company" or the "Registrant") will eliminate the position of Chief Scientific Officer. Dr. Christian Heidbreder will continue to report to the CEO in an advisory capacity on special projects through the end of 2026. Dr. Heidbreder's employment will terminate on December 31, 2026, and his termination will be treated as a termination without cause pursuant to the terms of his existing employment agreement with the Company.

Indivior Pharmaceuticals Inc. published this content on May 15, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on May 15, 2026 at 20:04 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]